Cyramza 100 mg Injection
584,16$
480,49$
Cyramza 100 mg injection is a targeted monoclonal antibody therapy designed to combat various types of cancer, including gastric and lung cancers. This innovative medication works by specifically inhibiting the vascular endothelial growth factor receptor 2 (VEGFR2), a crucial protein involved in the formation of blood vessels that nourish tumors. By blocking VEGFR2, Cyramza effectively slows or halts the progression of cancerous cells, providing a vital option for patients undergoing treatment. It’s essential for patients to be aware of potential side effects, such as hypertension and gastrointestinal issues, and to discuss these with their healthcare provider. Regular monitoring during treatment is important to manage any adverse reactions effectively. Cyramza is typically administered in a healthcare setting, ensuring that patients receive the necessary support throughout their therapy. If you or a loved one are considering Cyramza as part of a cancer treatment plan, consult your oncologist to determine its suitability for your specific condition. This medication represents a significant advancement in cancer care, offering hope through targeted action against tumor growth.
Quantité
Active Pharmaceutical Ingredient
Uses
• Cyramza 100 mg injection is primarily used for the treatment of advanced stomach cancer. It works by targeting and inhibiting specific pathways that promote tumor growth. This helps to slow the progression of the disease in patients who have not responded adequately to previous therapies. The administration of Cyramza 100 mg injection is typically part of a comprehensive treatment plan.
• Patients with metastatic colorectal cancer can benefit from Cyramza 100 mg injection as well. This medication is often used in combination with other chemotherapy agents to enhance treatment efficacy. By blocking the vascular endothelial growth factor receptor, Cyramza 100 mg injection helps to reduce blood supply to the tumor. This can lead to improved outcomes for individuals facing this challenging condition.
• Cyramza 100 mg injection is also indicated for non-small cell lung cancer that has progressed despite prior treatments. It serves as an important therapeutic option for patients whose cancer has advanced beyond early stages. The drug's mechanism of action can help to manage the disease and potentially extend survival. Physicians often consider Cyramza 100 mg injection as part of a multi-faceted approach to lung cancer management.
• In addition to the aforementioned uses, Cyramza 100 mg injection is effective in treating hepatocellular carcinoma, a common type of liver cancer. This treatment is particularly beneficial for patients with advanced disease who are not candidates for surgical intervention. By targeting tumor vasculature, Cyramza 100 mg injection plays a critical role in controlling cancer growth. It is utilized in a carefully monitored treatment regimen to optimize patient outcomes.
Benefits
Gastric cancer: Gastric Cancer: Cyramza 100 mg Injection may be used alone or in combination with other chemotherapy drugs to treat advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) cancer. Cyramza 100 mg can help slow down disease progression and improve overall survival in patients with these types of cancer.
Colorectal cancer: Cyramza 100 mg Injection may be used with other chemotherapy medicines to treat metastatic colorectal cancer that has progressed after prior therapy. Cyramza Injection can delay tumor growth and extend survival in these patients.
Non-small cell lung cancer: Cyramza 100 mg Injection is prescribed for patients with advanced NSCLC, particularly those with certain molecular characteristics. Cyramza 100 mg may be used in combination with other anticancer medications to improve treatment outcomes.
Hepatocellular carcinoma (Liver Cancer): Cyramza 100 mg Injection is used for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha-fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.
Side Effects
Like all medicines, Cyramza 100 mg Injection may cause side effects such as high blood pressure, fatigue, nausea, vomiting, and diarrhoea. Tell your doctor if you have high blood pressure, bleeding problems, liver disease, kidney disease, lung cancer, or are going to have surgery before taking this medication. This medicine is not recommended for adolescents or children under 18 years of age.
Most Common Side Effects
• Sore throat
• Hypertension
• Nausea
• Vomiting
• Diarrhea
• Headache
• Chills
• Fever
• Fainting
• Nervousness
• Shivering
• Weakness
• Pounding in ears
• Seizures
Common Side Effects
• Visual Changes
• Rashes
• Dry mouth
• Feeling of Dehydration
• Decreased Urine
• Dizziness
• Loss of Appetite
• Dry Cough
• Productive Cough
• Painful Urination
• Pale skin
• Abdominal Cramps
• Slurred Speech
• Sweating
• Blurred Vision
• feeling of Numbness
How To Use
Cyramza 100 mg Injection should be given under the supervision of your healthcare professional as an infusion directly into a vein or intravenously. The dosage and duration of your medication will depend on many factors such as the severity of your illness, type of illness, age, weight, gender and other medical conditions. It is a good idea to tell your doctor or health care professional about all other medicines you are taking or are being treated with. Avoid using this medicine if you are pregnant or breastfeeding as safety in these patients has not been established.
Safety Advice
• Alcohol: It is generally recommended that patients taking {Product_namee_two} should avoid or reduce their alcohol intake as alcohol can increase the risk of liver damage and worsen any liver-related side effects of this medicine.
• Kidney: Cyramza 100 mg Injection should be used with extreme caution in patients with kidney disease due to the increased risk of worsening of the patient's condition. Close monitoring of kidney function is essential while taking this Cyramza 100 mg. Appropriate dose adjustment or substitution with a suitable alternative may be required in some cases depending on the clinical condition of the patient.
• Breastfeeding: The excretion of Cyramza 100 mg Injection in human milk remains uncertain. It is expected that excretion in milk and oral absorption will be minimal. Due to the potential risk to breastfeeding infants, it is recommended that breastfeeding be discontinued during treatment with Cyramza 100 mg and for at least three months after the remaining dose.
• Liver: Cyramza 100 mg Injection should be used with extreme caution in patients with liver disease due to the increased risk of worsening the patient's condition. Close monitoring of liver function is essential while taking this medicine. Appropriate dose adjustment or substitution with a suitable alternative may be required in some cases depending on the clinical condition of the patient.
• Pregnancy: Cyramza 100 mg Injection is not recommended during pregnancy or in women of childbearing potential who are not using contraception. Women of childbearing potential should be advised not to become pregnant while taking Cyramza Injection and should be counselled about the potential hazards to pregnancy and the foetus. Women of childbearing potential should use effective contraception during and for up to 3 months after the last dose of Cyramza 100 mg Injection.
• Driving: Cyramza 100 mg Injection has no or negligible effect on the ability to drive or use machinery. If patients experience symptoms that affect their ability to concentrate and react, it is recommended that they do not drive or use machinery until the effects have subsided.